2,6-Bis(2,6-diethylphenyliminomethyl)pyridine coordination compounds with cobalt(II), nickel(II), copper(II), and zinc(II): synthesis, spectroscopic characterization, X-ray study and in vitro cytotoxicity Pablo Mart´ınez-Bulit, Ariadna Garza-Ort´ız, Edgar Mijangos, Lidia Barr´onSosa, Francisco S´anchez-Bart´ez, Isabel Gracia-Mora, Angelina Flores-Parra, Rosalinda Contreras, Jan Reedijk, Nor´ah Barba-Behrens PII: DOI: Reference:

S0162-0134(14)00249-9 doi: 10.1016/j.jinorgbio.2014.09.007 JIB 9598

To appear in:

Journal of Inorganic Biochemistry

Received date: Revised date: Accepted date:

14 March 2014 12 September 2014 12 September 2014

Please cite this article as: Pablo Mart´ınez-Bulit, Ariadna Garza-Ort´ız, Edgar Mijangos, Lidia Barr´ on-Sosa, Francisco S´ anchez-Bart´ez, Isabel Gracia-Mora, Angelina Flores-Parra, Rosalinda Contreras, Jan Reedijk, Nor´ah Barba-Behrens, 2,6Bis(2,6-diethylphenyliminomethyl)pyridine coordination compounds with cobalt(II), nickel(II), copper(II), and zinc(II): synthesis, spectroscopic characterization, X-ray study and in vitro cytotoxicity, Journal of Inorganic Biochemistry (2014), doi: 10.1016/j.jinorgbio.2014.09.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT Manuscript JIB-14-03225R2, Final; September 12 2014 coordination

PT

2,6-Bis(2,6-diethylphenyliminomethyl)pyridine

compounds with cobalt(II), nickel(II), copper(II), and zinc(II):

RI

synthesis, spectroscopic characterization, X-ray study and in

SC

vitro cytotoxicity

NU

Pablo Martínez-Bulita, Ariadna Garza-Ortíza,1, Edgar Mijangosb,2, Lidia Barrón-

MA

Sosaa,c, Francisco Sánchez-Bartéza,c, Isabel Gracia-Moraa,c, Angelina FloresParrab, Rosalinda Contrerasb, Jan Reedijkd,e, Noráh Barba-Behrensa*

TE

D

a) Departamento de Química Inorgánica, Facultad de Química, Universidad Nacional Autónoma de México, C.U., Coyoacán, México D.F. 04510, México b) Departamento de Química, CINVESTAV, AP 14-740, México D.F. 07000, México

AC CE P

c) Unidad de Experimentación Animal, Facultad de Química, Universidad Nacional Autónoma de México, C.U., Coyoacán, México D.F. 04510, México d) Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands e) Department of Chemistry, College of Science, King Saud University, P.O. Box 2455 Riyadh 11451, Kingdom of Saudi Arabia. *Correspondig author: Noráh Barba-Behrens, [email protected], +52 (55) 5622 3810 1

Present address: Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Villa Quietud, México D.F. 04960, México 2

Present address: Department of Chemistry - Ångström Laboratory, Uppsala Universitet, P.O. Box 523, 75120 Uppsala, Sweden

1

ACCEPTED MANUSCRIPT Abstract Coordination compounds with cobalt(II), nickel(II), copper(II) and zinc(II) and the ligand

PT

2,6-bis(2,6-diethylphenyliminomethyl)pyridine (L) were synthesized and fully characterized

RI

by IR and UV-Vis-NIR spectroscopy, elemental analysis, magnetic susceptibility and X-ray diffraction for two representative cases. These novel compounds were designed to study

SC

their activity as anti-proliferative drugs against different human cancer cell lines. The

NU

tridentate ligand forms heptacoordinated compounds from nitrate metallic salts, where the nitrate acts in a chelating form to complete the seven coordination positions. In vitro cell

MA

growth inhibition was measured for CoII, CuII and ZnII complexes, as well as for the free ligand. Upon coordination, the IC50 value of the transition-metal compounds is improved

D

compared to the free ligand. The copper(II) and zinc(II) compounds are the most promising

TE

candidates for further in vitro and in vivo studies. The activity against colon and prostate

types. Keywords:

AC CE P

cell lines merits further research, in views of the limited therapeutic options for such cancer

Heptacoordinated

compounds;

cytotoxicity; cobalt(II); copper(II); nickel(II); zinc(II)

2

2,6-bis(arylimino)pyridine

derivatives;

ACCEPTED MANUSCRIPT 1. Introduction 2,6-Bis(arylimino)pyridine ligands, members of the Schiff bases family, have been widely

PT

studied over the last decades due to their diverse chemical properties [1-5]. The possibility

RI

to expeditiously fine-tune their steric and electronic properties, as well as the donor atoms nature and number, make these ligands attractive for coordination chemistry studies and

SC

their applications on different fields such as catalysis, medicinal inorganic chemistry and

NU

magnetic devices [1, 5-9]. Moreover, it has been shown that changes in the ligand structure can lead to a change in the chemical properties of the coordination compounds

MA

[10]. Studies regarding the catalytic applications of Schiff base-metal complexes have shown that there are various synthetic routes for the complex formation, where the metallic

D

precursor and the solvent can play important roles [11]. This fact broadens the diversity of

AC CE P

syntheses.

TE

Schiff base-metal catalysts and confers them with a unique flexibility during their

The chemical structure of 2,6-bis(arylimino)pyridine ligands allows strong and stable bonding with several metallic atoms, where the large conjugated system helps to stabilize several oxidation states as well as free radicals [12]. Coordination complexes with this type of ligands and mainly FeII and CoII have been investigated as olefin polymerization catalysts, and their activity was surprisingly high given their chemical structure [3-5, 1317]. Other studies have shown the cytotoxic effect of RuII/III complexes [6, 7], as well as the anti-inflammatory properties of organotin(IV) compounds [18]. Finally, there are reports of the synthesis of 2,6-bis(arylimino)pyridine complexes with VIII, CrII, III, MnII, FeIII, NiII, CuII, ZnII, PdII, with diverse applications, but mainly focused on catalysis [19-25]. Since the discovery of the cisplatin antiproliferative properties, almost 50 years ago [26], a large number of metal complexes have been tested as anti-cancer drugs in an effort to

3

ACCEPTED MANUSCRIPT find compounds with higher selectivity and less side effects than those commercially available [27-29]. The aim of the present study is to provide a new perspective on this

PT

issue, by designing coordination compounds with first-row transition metals and ligands

their presence in the human body as trace elements.

RI

that show unusual chemical characteristics. The selection of the metal ions is based on

SC

In this work, the tridentate ligand 2,6-bis(2,6-diethylphenyliminomethyl)pyridine (L)

NU

coordination behavior was studied in the presence of four transition metals (Co II, NiII, CuII, and ZnII). The complexes were characterized by UV-Visible (UV-Vis)-NIR and IR

MA

spectroscopy, elemental analysis, magnetic susceptibility, and single crystal X-ray diffraction in case good quality monocrystals could be obtained. The biological activity was

D

assessed through a human cancer cell-growth inhibitory assay and the IC50 values were

AC CE P

activity relationships.

TE

calculated and the results are analyzed and discussed in order to formulate structure

2. Experimental Section 2.1 Physical measurements

IR spectra in the range 4000-400 cm-1 were obtained on a Perkin Elmer FT-IR 1605 Spectrum spectrophotometer with the sample prepared as a KBr pellet, at 298 K. Electronic spectra were recorded using a Cary 5000 Varian Spectrophotometer by the diffuse reflectance method, in the 40000-5000 cm-1 range at 298 K. Elemental analyses were carried out with a Fisons EA 1108 analyzer. Magnetic susceptibility measurements at ambient temperature were recorded on a Johnson-Matthey MSB (Magnetic Susceptibility Balance) type MK II 13094-3002, using the Gouy method. 1H and

13

C NMR spectra were

recorded using a JEOL 400 MHz spectrometer. The chemical shifts were referenced to TMS (tetramethylsilane). EPR spectra of powder samples were recorded with a Bruker 4

ACCEPTED MANUSCRIPT Elexsys E500 spectrometer using the X-band (9.45 GHz) microwave frequency operating at 100 kHz. g values were calculated using the microwave frequency and measuring the

PT

magnetic field H.

RI

2.2 X-Ray crystal structure determination

SC

X-ray diffraction data were collected on a Bruker Kappa CCD area detector diffractometer using Mo-Kα (λ = 0.71073 Å) radiation at 293(2) and 173(2) K. The samples

NU

were mounted on MicroMounts (MiTeGen company) [30] with paratone-N oil. Data collection, determination of unit cell and integration of frames were carried out using the

MA

suite Collect software [31]. Intensities were measured using φ + ω scans. Structure solution and refinement were carried out with the program SHELXL-97 [32]. All

D

crystallographic software was used under WinGX program [33]. All non-hydrogen atoms

TE

were refined anisotropically and all hydrogen atoms were placed geometrically and

AC CE P

allowed to ride on their respective atoms. The crystallographic details are summarized in Table 1. Selected bond lengths and angles are listed in Table 2. Crystallographic data for structures 1 and 4 have been deposited at the Cambridge Crystallographic Data Centre as supplementary publication CCDC 991489 and 991490. Copies of the structures can be obtained free of charge www.ccdc.cam.ac.uk/data_request/cif. 2.3 Reagents The chemicals and analytical reagents were purchased from various commercial sources

and

were

used

without

further

purification

unless

otherwise

stated.

Co(NO3)2·6H2O, Ni(NO3)2·6H2O, Cu(NO3)2·3H2O, Zn(NO3)2·6H2O and solvents from J. T. Baker. 2,6-pyridinedimethanol and 2,6-diethylaniline from Aldrich. Dry solvents, when required, were prepared using standard procedures. 2.4 Synthesis 5

ACCEPTED MANUSCRIPT 2.4.1 2,6-bis(2,6-diethylphenyliminomethyl)pyridine (L)

2,6-diethylaniline

(1.53

g,

10

mmol)

was

added

PT

Ligand L [6] and 2,6-pyridinedicarboxaldehyde [34] were synthesized as reported. to

a

solution

of

2,6-

RI

pyridinedicarboxialdehyde (0.68 g, 5 mmol) in absolute methanol. The resulting mixture

SC

was refluxed for 6 h over molecular sieves (4 Å) and filtered while hot. Upon cooling, a pale yellow solid was obtained (1.72 g, 87 %). IR (KBr, cm-1): 3434 (w, b), 3064 (m), 3017

NU

(w), 2964-2870 (s), 1643 (s), 1587 (m), 1564 (m), 1458 (s), 1337 (m), 1189 (s), 854 (m), 792 (m), 759 (m). NMR (400 MHz, CDCl3,  ppm, s=singlet, d=doublet, t=triplet,

MA

m=complex pattern) 1H: 8.4013 (d, 2H; H4, H6), 8.3960 (s, 2H; H2, H9), 7.9979 (t, 1H; H5), 7.1341-7.0686 (m, 6H, H13A, H14A, H15A, H23A, H24A, H25A), 2.5412 (dd, 8H, 2H17A, 2H19A, 13

D

2H27A, 2H29A) and 1.1667 (t, 12H, 3H18A, 3H20A, 3H28A, 3H30A).

C: 162.8956 (C3, C7),

TE

154.5375 (C2, C9), 149.6053(C5) 137.4468 (C11A, C21A), 132.7822 (C12A, C16A, C22A, C26A),

AC CE P

126.3741 (C13A, C15A, C23A, C25A), 124.4624 (C4, C6), 122.7418 (C14A, C24A), 24.7853 (C17A, C19A, C27A, C29A), 14.6761 (C18A, C20A, C28A, C30A). UV-Vis: 25750 cm-1. Anal. for C27H31N3: Calc. (%): C, 81.57; N, 10.57; H, 7.86. Found (%): C, 81.82; N, 10.63; H, 7.69. 2.4.2 Synthesis

of

2,6-bis(2,6-diethylphenyliminomethyl)pyridinebis(nitrato)cobalt(II)

[Co(L)(NO3)2] (1). General synthetic procedure for compounds 1-4. A solution of Co(NO3)2·6H2O (87 mg, 0.3 mmol) in acetonitrile (30 mL) was added to a solution of L (119 mg, 0.3 mmol) in acetonitrile (30 mL). The mixture was refluxed 4 h and filtered while hot. After 2 days, brownish crystals suitable for X-ray diffraction (XRD) studies were isolated (62.6 mg, 36%). IR (KBr, cm-1): 3412 (w, b), 3072 (w) 2968-2876 (m), 1627 (w), 1586 (m), 1469 (s, b), 1384 (vs), 1288 (s), 1162 (w), 1026 (w), 808 (w), 762 (w), 745 (w). µeff at room temperature (RT): 4.99 BM. Anal. for [Co(C27H31N3)(NO3)2]: Calc. (%): C, 55.86; N, 12.06; H, 5.38. Found (%): C, 55.94; N, 12.19; H, 5.27. The isolated

6

ACCEPTED MANUSCRIPT crystals had non-coordinated acetonitrile crystallization molecules, as shown in the XRD (vide infra), which were lost upon standing at room temperature (RT). of

2,6-bis(2,6-diethylphenyliminomethyl)pyridinebis(nitrato)nickel(II)

PT

2.4.3 Synthesis

RI

[Ni(L)(NO3)2]·3H2O (2)

Ni(NO3)2·6H2O (87 mg, 0.3 mmol); L (119 mg, 0.3 mmol). After one week, from the

SC

acetonitrile solution a brown microcrystalline solid was filtered and washed with cold CHCl3

NU

(73.6 mg, 39%). IR (KBr, cm-1): 3435 (w, b), 3071 (w) 2967-2876 (m), 1616 (w), 1584 (m), 1470 (s, b), 1384 (vs), 1297 (s), 1163 (w), 1015 (w), 806 (w), 759 (w), 744 (w). µeff (at RT):

MA

3.32 BM. Anal. for [Ni(C27H31N3)(NO3)2]·3H2O Calc. (%): C, 51.13; N, 11.04; H, 5.88. Found (%): C, 50.63; N, 11.51; H, 5.13. The small deviation is %H could be due to loss of

of

AC CE P

[Cu(L)(NO3)2] (3)

2,6-bis(2,6-diethylphenyliminomethyl)pyridinebis(nitrato)copper(II)

TE

2.4.4 Synthesis

D

some water during analysis, but the IR spectra are mutually almost indistinguishable.

Cu(NO3)2·3H2O (72 mg, 0.3 mmol); L (119 mg, 0.3 mmol). The evaporation of acetonitrile afforded a microcrystalline deep-green solid (162 mg, 92%). IR (KBr, cm-1): 3387 (w, b), 3071 (w) 2967-2875 (m), 1627 (w), 1589 (m), 1462 (s, b), 1384 (vs), 1288 (s), 1162 (w), 1019 (w), 808 (w), 761 (w). µeff (at RT): 1.72 BM. Anal. for [Cu(C27H31N3)(NO3)2]: Calc. (%): C, 55.42; N, 11.97; H, 5.34. Found (%): C, 55.50; N, 10.99; H, 5.26. The low experimental value for %N is not understood, but given the other characterization there is no doubt on the composition. 2.4.5 Synthesis

of

2,6-bis(2,6-diethylphenyliminomethyl)pyridinebis(nitrato)zinc(II)

[Zn(L)(NO3)2] (4) Zn(NO3)2·6H2O (89 mg, 0.3 mmol); L (119 mg, 0.3 mmol). After 2 days, the acetonitrile solution afforded yellow crystals suitable for X-ray diffraction study (99 mg, 56%). IR (KBr, cm-1): 3456 (w, b), 3074 (w) 2969-2876 (m), 1639 (w), 1591 (m), 1469 (s, b), 1384 (vs), 7

ACCEPTED MANUSCRIPT 1283 (s), 1163 (w), 1010 (w), 811 (w), 763 (w), 745 (w). Anal. for [Zn(C27H31N3)(NO3)2]: Calc. (%): C, 55.25; N, 11.93; H, 5.32. Found (%): C, 55.09; N, 11.92; H, 5.18. The

PT

isolated crystals had acetonitrile crystallization molecules in the lattice, which were lost

RI

upon standing at RT.

SC

2.5. Measurements of cell growth inhibition

Details of measuring cell growth inhibition are described elsewhere [35]. Human cancer colon (HTC-15), breast (MCF-7) and prostate (PC-3) were

NU

cell lines: cervix (HeLa),

acquired from ATCC (American Tissue Culture Collection) and maintained in incubation at

with

10%

BFS

(GIBCO®,

MA

310 K and 5% CO2 with RPMI medium (GIBCO®, Invitrogen corporation) supplemented Invitrogen

corporation),

1%

L-glutamine

and

1%

D

penicillin/streptomycin. Experiments were performed with cells within at least five

TE

passages from each other. All cells were split when around 80–95% confluence was

AC CE P

reached using 0.25% trypsin/EDTA. The EDTA/trypsin solution was used to recover the cells from the culture stock and seeded in a 96 wells plate, where the coordination compound is added with fresh culture medium, as detailed below. In the in vitro growth inhibition assay, 2 × 104 cells/well were plated in a 96-well microplate with D-MEM supplemented with 10% BFS, and allowed to attach, incubating at 37 °C and 5% CO2 for 24 h. At the end of incubation time, the medium was put under vacuum and the cells were exposed to drugs in five different concentrations (0, 10, 20, 30 and 40 μg/mL) for 48 h under the conditions mentioned above. Cell growth was determined according to the sulforhodamine B assay (SRB assay), described by Skehan [36, 37]. Absorbance was measured at 564 nm (microplate reader Bio-Rad 550) and the percentage cell growth for each concentration of drug was calculated as: percentage growth = 100 × [T/C], where T is the absorbance of treated wells and C is the absorbance of untreated wells. The 50% growth inhibition parameter (IC50) was computed with a log 8

ACCEPTED MANUSCRIPT probit analysis by maximum likelihood employing the software SPSS 20 [38]. The variability of the in vitro cytotoxicity test depends on the cell line used and the serum

PT

applied. With the same batch of cell lines and the same batch of serum the interexperimental CV (coefficient of variation) is 1–11%, depending on the cell line and the

RI

intra-experimental CV is 2–4%. These values may be higher when using other batches of

SC

cell lines and/or serum.

NU

3. Results and discussion

Ligand

L

was

synthesized

MA

3.1 Spectroscopic characterization by

condensation

of

one

equivalent

of

2,6-

D

pyridinedicarboxaldehyde and 2,6-diethylaniline in methanol with high yield. The ligand

AC CE P

Figure 1, for numbering).

TE

was fully characterized by spectroscopy and comparison with related systems [6, 7] (see

Reaction of the ligand and the nitrates of CoII, NiII, CuII, and ZnII, in acetonitrile, resulted in the corresponding coordination compounds [M(L)(NO3)2] (1-4). In the coordination compounds the ligand bands (C=N) imine (1643; 1458 cm-1) are shifted (1616-1639; 1462-1470 cm-1), [6, 7] indicative on the metal coordination through the nitrogen atoms. New bands at 1384, 1288 (3), 1015 (1) and 810(2) cm-1 corresponding to coordinated nitrate ligands were observed in all complexes, indicating a bidentate coordination mode [39-41]. Bands corresponding to aryl and pyridine rings out of plane vibrations (792 and 759 cm-1) are shifted to higher vibrational energies in the coordination compounds. All relevant infrared spectra are shown in the supplementary information (Figures S1-S5). The electronic spectra of this family of coordination compounds are complex and show several d-d transitions in compounds 1 and 2, preceding the strong charge transfer band 9

ACCEPTED MANUSCRIPT (CT) and are consistent with the heptacoordinated crystal field splitting [42]. Composed bands centered in 7576, 13084, and a shoulder at 16384 cm-1, at the edge of a CT (charge

PT

transfer) band, are observed for cobalt(II) compound (1). For the nickel(II) compound (2), bands centered in 9669, 12458, 15034, and a shoulder at 20000 cm-1 are observed. In

RI

both spectra, a broad charge-transfer band is observed in the 25000 cm-1 region, indicative

SC

of a large electronic delocalized system, where the metal ion also participates as a member of the conjugated rings. In the case of the spectrum for the copper(II) compound

NU

(3) an unresolved broad band is seen, from which the d-d transition is not clearly visible. In

MA

the zinc(II) compound (4) the →* transition is shifted to lower energy. The electronic spectra are shown in the supplementary information, Figures S6-S9).

D

3.2 Magnetic susceptibility

TE

Effective magnetic moments for compounds 1-3 at ambient temperature are shown in

AC CE P

the experimental section. All the results are close to predicted values within the expected range for the metal center in 2+ oxidation state, with a high spin configuration for cobalt(II) The EPR spectrum of copper(II) compound (3) at RT did not showed any hyperfine interactions between the ligand L and the metal ion. The observed pseudo-isotropic gvalue is consistent with CuII: g = 2.11. The EPR spectrum is shown in the supplementary information (Figure S10). 3.3 Crystal structures Cobalt(II) compound 1 crystallizes in the P21/n space group with four coordination entities in the asymmetric unit. A heptacoordinated metallic center with a distorted pentagonal bipyramidal (PBP) geometry is present (Figure 2). The equatorial plane around the CoII center is formed by the pyridine nitrogen atom N8 and the four oxygen atoms from the nitrato ligands, while the imine nitrogen atoms N1 and N10 occupy the axial positions 10

ACCEPTED MANUSCRIPT A bidentate coordination of the nitrato ligand has been observed in other CoII compounds [43]. The ligand chelate angles produce a distortion of the axial nitrogen N1-Co-N10 angle

PT

[149.90(6)°].

RI

Only one oxygen atom from each chelating nitrato ligand is in the equatorial plane. Possible explanations for this twisted arrangement of the nitrato ligands are O31-O35

SC

repulsion and possible weak cooperative intermolecular hydrogen bonds generating

NU

dimers (See Figure S12)

The Co-N distance for the pyridine nitrogen of [2.061(1) Å] is slightly shorter than the

MA

Co-N distance for the imine nitrogen atoms [2.250(1) and 2.280(1) Å]. The M-N1 and M-N10 coordination bonds do not have identical bond lengths, the origin for this small

D

difference is that in the crystal packing the molecules are slightly asymmetric oriented,

TE

dictated by the space group; see also Figure S13.

AC CE P

The Co-O bond lengths vary from 2.117(1)-2.312(1) Å. The aniline rings are almost perpendicular to the pyridine ring, which is the result of the steric bulk of the ethyl groups. A projection of the structure depicting this orientation is given in Figure S11. Selected angles and bond distances are presented in Table 2.

11

ACCEPTED MANUSCRIPT Intermolecular interactions in compound 1 are formed by -stacking interactions and weak OHC bonds. The orientation of the ethyl substituents also appears to play a role in

PT

this interaction, allowing the  conjugated systems to efficiently overlap. This is confirmed by the stacking distance between the planes (3.46 Å); the opposite ring, on N1, where the

RI

ethyl groups are not correctly oriented, is unable to interact in this way with other

SC

molecules. This stacking also facilitates the weak hydrogen bonding between one of the coordinated nitrato oxygen atoms and a hydrogen atom of the aromatic ring. This bond

NU

perhaps also stabilizes the PBP’s equatorial plane distortion. The other contribution to the

MA

structure distortion is made by a hydrogen bond between the coordinated oxygen atom (O35) and a carbon atom (C5) from the pyridine ring (See Figure S14).

D

Intramolecular interactions in the cobalt(II) compound 1 are of great interest due to their

TE

distribution. Four weak hydrogen bonds between a methylene from the substituent groups and the equatorial nitrato oxygen atoms (O33, O37) are disposed in a square-type arrangement

AC CE P

(Figure 3).

All these hydrogen bonds can be classified as weak electrostatic interactions, according to Steiner [44]. The bond distances are large and the orientation of the involved atoms is far from optimal. Finally, the lattice acetonitrile molecules are weakly interacting with coordination compound molecules as can be seen in Figure S15 and in the 3D arrangement (see Figure S16). The involved HA and DA distances are the following: H9N39, 2.961 Å; H41AO37, 2.606 Å; H41AN39, 2.738 Å; C41O31, 3.230 Å;C9N39, 3.112 Å; C41N39, 3.464 Å. The zinc(II) compound (4) crystallizes in the P21/c space group. The metal ion also presents a heptacoordination, with the three L nitrogen atoms and two oxygen atom of each nitrate coordinated towards it (Figure 4). As in the cobalt(II) compound (1), the Zn-N

12

ACCEPTED MANUSCRIPT distance is relatively shorter for the pyridine nitrogen, N8, (2.021 Å) compared to the imine nitrogen atoms, N1 and N10, (2.313 and 2.260 Å, respectively), Figure S18

PT

The nitrate ligands are coordinated also in a bidentate form, with asymmetric bonds. The

RI

oxygen atoms O31 and O35 are at distance to the ZnII center of 1.989(1) and 1.999(1) Å respectively, while oxygen atoms O33 and O37 distance to the metallic center is 2.749(2)

SC

and 2.695(2) Å respectively. This long distance is still shorter than the sum of zinc(II) and

NU

oxygen van der Waals radii [45]. Similar heptacoordinated zinc(II) structures have been reported [46, 47]. Compared to the Co(II) compound the nitrate ligands are more

MA

asymmetric, which can be ascribed to the smaller size of Zn(II) compared to Co(II). Studying the crystalline packing, several weak hydrogen bond interactions can be seen.

D

Four intramolecular hydrogen bonds are present in the structure, in a similar arrangement

TE

than in the cobalt(II) structure (See Figure S19).

AC CE P

These weak hydrogen bonds involve the imine nitrogen atoms, one oxygen atom from each nitrate ion and four carbon atoms from the ethyl moieties as donor atoms. This arrangement apparently helps to minimize the energy of the structure and stabilize the crystalline lattice. Intermolecular hydrogen bonds are established between backbone hydrogen atoms and the oxygen atoms from the nitrato groups (See Figure S20). Two different -stacking interactions were observed; one involves the pyridine ring and a phenyl ring (Figure 5), and the other one is established between two phenyl rings (Figure 6). The distance between the aromatic planes and the position of the rings are within the expected range for this kind of systems [48], as can be seen on Figure 6. These -stacking interactions, in combination with weak hydrogen bond interactions stabilize a supramolecular 3D arrangement (See Figure S21). It is important to note that, although the structure of compounds 1 and 4 is similar, the supramolecular arrangement in

13

ACCEPTED MANUSCRIPT the crystal lattice differs significantly between the two structures, which is ascribed to difference in size of the cation, resulting in a different space group.

PT

Both crystalline structures of compounds 1 and 4 exhibit a dynamic disorder on the phenyl substituted rings. In the cobalt(II) compound 1 this disorder is located only in one of

RI

the rings, where all the atoms have two possible positions; in the zinc(II) compound 4 both

SC

rings exhibit this type of disorder, even though the data collection was done at low

NU

temperature.

Based on the X-ray structure determination, spectroscopic data, elemental analyses, and

MA

magnetic susceptibility measurements, the proposed structure for the other 2 compounds is shown in Figure 7.

D

The number of seven-coordinated transition metal compounds found in the literature is

TE

relatively low [49], but the role that these type of compounds play as reaction

AC CE P

intermediates in substitution reactions or active sites in enzymes [50-52] is seen as of great importance.

3.4 Cancer cell growth inhibition In solution all coordination compounds appeared to have the coordinated nitrate anions exchanged by water molecules, which is in agreement with their conductivity measurements (in CH3CN/H2O). The metal ions remain coordinated to the ligand, as deduced from their electronic spectra in solution. Of course we cannot exclude that in real water (about 55 molar) water or other biomolecules present in mM concentrations, like amino acids) may also bind. To explore the biological activity of 3 of the metal compounds and the free ligand presented in this research work, against cancer cell line proliferation, the in vitro cytotoxicity via the SRB assay was performed. The cytotoxicity of this family of 2,614

ACCEPTED MANUSCRIPT bis(arylimino)pyridine compounds, with cisplatin as reference compound, was studied in the following human cancer cell lines: HCT-15 (colon adenocaricinoma), PC-3 (prostate MCF-7

(breast

adenocarcinoma)

and

HeLa

(cervical

uterine

PT

adenocarcinoma),

adenocarcinoma). The IC50 value represents the amount of drug needed to inhibit 50% of

RI

the cancer cell growth, and it was obtained after 48 h of exposition (Table 3). The nickel(II)

SC

compound, 3, was not investigated in this work, as previous studies in our group had shown poor antiproliferative activity for compounds with this metal center and related

NU

ligands [53].

MA

The ligand L shows the lowest cytotoxic effect. In contrast, 1, 3 and 4, show an important increment when compared with the free L, which underlines the effect of the metal center

D

in the cytotoxic activity. The most active compounds showed IC50 values ranging from 25-

TE

53 µM. These results are seen as promising, considering other first-row transition metalbased compound values determined by our group [53, 54]. Of course it cannot be totally

AC CE P

excluded that under high dilution conditions, where the tests are done, some further decomposition may have occurred. The copper(II) and zinc(II) compounds are the most promising candidates for further in vitro and in vivo studies.

4. Conclusions Four

new

transition

metal

nitrate

compounds

with

a

new

tridentate

2,6-

bis(arylimino)pyridine ligand are reported. For the cobalt(II) and zinc(II) compounds a heptacoordinated geometry was determined in the 3D solid state and a similar structure is proposed for the nickel(II) and copper(II) compounds. The in vitro cytotoxic activity of compounds 1, 3 and 4, and ligand L was assessed, showing a moderate, yet promising activity against the studied cell lines; the coordination

15

ACCEPTED MANUSCRIPT compounds proved to be more active than the free ligand, especially in the case of the copper(II) compound 3.

PT

Upon coordination, the IC50 values of the transition-metal compounds are improved

RI

compared to the free ligand under the same conditions and selectivity was observed towards prostate and colon adenocarcinomas. The activity against these cell lines merits

NU

SC

further research, in views of the limited therapeutic options for such cancer types.

MA

Acknowledgements

We are grateful to DGAPA (Grant IN 222713) and Conacyt (CB-2012 178851) for

D

financial support. EM thanks the post-doctoral fellowship provided by the CONACyT Grant

TE

60894-CB. AGO expresses gratitude to CONACyT and UAM-Xochimilco for postdoctoral fellowships. We thank Carlos Camacho-Camacho for his valuable contribution to the

for support.

AC CE P

discussion of this work. One of us (JR) thanks the DSF Program of King Saud University

Supporting information

Selected intramolecular and intermolecular interactions in the crystalline structures of cobalt(II) and zinc(II) compounds can be consulted in the SI. Infrared, electronic and EPR spectra are also shown in the SI.

References [1] V.C. Gibson, C. Redshaw, G.A. Solan, Chem. Rev., 107, (2007), 1745-1776 [2] B.L. Small, M. Brookhart, A.M.A. Bennett, J. Am. Chem. Soc., 120, (1998), 4049-4050 [3] I.E. Soshnikov, N.V. Semikolenova, A.N. Bushmelev, K.P. Bryliakov, O.V. Lyakin, C. Redshaw, V.A. Zakharov, E.P. Talsi, Organometallics, 28, (2009), 6003-6013 16

ACCEPTED MANUSCRIPT

AC CE P

TE

D

MA

NU

SC

RI

PT

[4] G.J.P. Britovsek, M. Bruce, V.C. Gibson, B.S. Kimberley, P.J. Maddox, S. Mastroianni, S.J. McTavish, C. Redshaw, G.A. Solan, S. Stromberg, A.J.P. White, D.J. Williams, J. Am. Chem. Soc., 121, (1999), 8728-8740 [5] C. Bianchini, G. Giambastiani, I. Rios, G. Mantovani, A. Meli, A. Segarra, Coord. Chem. Rev., 250, (2006), 1391-1418 [6] A. Garza-Ortiz, P.U. Maheswari, M. Siegler, A.L. Spek, J. Reedijk, Inorg. Chem., 47, (2008), 6964-6973 [7] A. Garza-Ortiz, P.U. Maheswari, M. Siegler, A.L. Spek, J. Reedijk, New J. Chem., (2013), 37, 3450-3460 [8] K. Tenza, M.J. Hanton, A.M.Z. Slawin, Organometallics, 28, (2009), 4852-4867 [9] C. Gorl, N. Beck, K. Kleiber, H.G. Alt, J. Mol. Catal. A Chem., 352, (2012), 110-127 [10] J. Campora, M.A. Cartes, A. Rodriguez-Delgado, A.M. Naz, P. Palma, C.M. Perez, Inorg. Chem., 48, (2009), 3679-3691 [11] P.G. Cozzi, Chem. Soc. Rev., 33, (2004), 410-421 [12] D. Enright, S. Gambarotta, G.P.A. Yap, P.H.M. Budzelaar, Angew. Chem. Int. Edit., 41, (2002), 3873-3876 [13] B.L. Small, M. Brookhart, J. Am. Chem. Soc., 120, (1998), 7143-7144 [14] C. Görl, H.G. Alt, J. Organomet. Chem., 692, (2007), 4580-4592 [15] Y. Chen, R. Chen, C. Qian, X. Dong, J. Sun, Organometallics, 22, (2003), 4312-4321 [16] Y. Chen, C. Qian, J. Sun, Organometallics, 22, (2003), 1231-1236 [17] V.C. Gibson, N.J. Long, P.J. Oxford, A.J.P. White, D.J. Williams, Organometallics, 25, (2006), 1932-1939 [18] A. Gonzalez, E. Gomez, A. Cortes-Lozada, S. Hernandez, T. Ramirez-Apan, A. NietoCamacho, Chem. Phar. Bull., 57, (2009), 5-15 [19] C. Gorl, T. Englmann, H.G. Alt, Appl. Catal. A Gen., 403, (2011), 25-35 [20] M. Bröring, C. Kleeberg, E. Cónsul Tejero, Eur. J. Inorg. Chem., 2007, (2007), 32083216 [21] R. Balamurugan, M. Palaniandavar, M.A. Halcrow, Polyhedron, 25, (2006), 1077-1088 [22] I.J. Blackmore, V.C. Gibson, P.B. Hitchcock, C.W. Rees, D.J. Williams, A.J.P. White, J. Am. Chem. Soc., 127, (2005), 6012-6020 [23] B. de Bruin, E. Bill, E. Bothe, T. Weyhermuller, K. Wieghardt, Inorg. Chem., 39, (2000), 2936-2947 [24] F. Calderazzo, U. Englert, G. Pampaloni, R. Santi, A. Sommazzi, M. Zinna, Dalton Trans., (2005), 914-922 [25] I. Vidyaratne, J. Scott, S. Gambarotta, R. Duchateau, Organometallics, 26, (2007), 3201-3211 [26] B. Rosenberg, L. Van Camp, T. Krigas, Nature, 205, (1965), 698-699 [27] P. Köpf-Maier, Eur. J. Clin. Pharmacol., 47, (1994), 1-16 [28] Z.J. Guo, P.J. Sadler, Adv. Inorg. Chem., Vol 49, 49, (2000), 183-306 [29] Z.J. Guo, P.J. Sadler, Angew. Chem. Int. Edit., 38, (1999), 1513-1531 [30] www.mitegen.com. [31] Nonius COLLECT, Nonius BV: Delft, The Netherlands, 1998. [32] G. Sheldrick, Acta Cryst. Section A, 64, (2008), 112-122 [33] L. Farrugia, J. Appl. Crystallogr., 32, (1999), 837-838 [34] A.L. Vance, N.W. Alcock, D.H. Busch, J.A. Heppert, Inorg. Chem., 36, (1997), 51325134 [35] M. Gielen, Appl. Organomet. Chem., 16, (2002), 481-494 [36] L.V. Rubinstein, R.H. Shoemaker, K.D. Paull, R.M. Simon, S. Tosini, P. Skehan, D.A. Scudiero, A. Monks, M.R. Boyd, J. Natl. Cancer. I., 82, (1990), 1113-1118 [37] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. Mcmahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, J. Natl. Cancer. I., 82, (1990), 1107-1112 17

ACCEPTED MANUSCRIPT

AC CE P

TE

D

MA

NU

SC

RI

PT

[38] M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, M.R. Boyd, Cancer Res., 48, (1988), 589-601 [39] K. Nakamoto, Infrared and Raman spectra of inorganic and coordination compounds. 5th ed.; Wiley: New York ; Chichester, 1997. [40] V. Chandrasekhar, B.M. Pandian, R. Azhakar, Polyhedron, 27, (2008), 255-262 [41] H. Liu, M. Du, X.J. Ge, X.H. Bu, M. Yang, Acta Cryst. E, 57, (2001), 100-102 [42] R.A. Levenson, R.G.J. Dominguez, Inorg. Chem., 12, (1973), 2342-2345 [43] C. Dowling, V.J. Murphy, G. Parkin, Inorg. Chem., 35, (1996), 2415-2420 [44] T. Steiner, Angew. Chem. Int. Edit., 41, (2002), 48-76 [45] S.S. Batsanov, Inorg. Mater., 37, (2001), 871-885 [46] A.I. Matesanz, I. Cuadrado, C. Pastor, P. Souza, Z. A. A. C., 631, (2005), 780-784 [47] A. Bino, N. Cohen, Inorg. Chim. Acta, 210, (1993), 11-16 [48] C. Janiak, J. Chem. Soc. Dalton, (2000), 3885-3896 [49] D. Casanova, P. Alemany, J.M. Bofill, S. Alvarez, Chem. Eur. J., 9, (2003), 1281-1295 [50] F.X. Gomisruth, L.F. Kress, J. Kellermann, I. Mayr, X. Lee, R. Huber, W. Bode, J. Mol. Biol., 239, (1994), 513-544 [51] H.M. Greenblatt, O. Almog, B. Maras, A. SpunginBialik, D. Barra, S. Blumberg, G. Shoham, J. Mol. Biol., 265, (1997), 620-636 [52] D. Zhang, D.H. Busch, P.L. Lennon, R.H. Weiss, W.L. Neumann, D.P. Riley, Inorg. Chem., 37, (1998), 956-963 [53] S. Betanzos-Lara, C. Gomez-Ruiz, L.R. Barron-Sosa, I. Gracia-Mora, M. FloresAlamo, N. Barba-Behrens, J. Inorg. Biochem., 114, (2012), 82-93 [54] O. Sánchez-Guadarrama, H. López-Sandoval, F. Sánchez-Bartéz, I. Gracia-Mora, H. Höpfl, N. Barba-Behrens, J. Inorg. Biochem., 103 (2009) 1204-1213

18

ACCEPTED MANUSCRIPT Table 1. Crystallographic data of compounds 1 and 4 1

4

Chemical formula Formula weight (g mol-1) Crystal size (mm) Crystal color Crystal system Space group Unit cell dimensions a (Å) b (Å) c (Å)  ()  ()  () V (Å3) Formula units Z Dcalc (g/cm3)  (mm-1) F(000) Temp (K)  range () Index range

[Co(C27H31N3)(NO3)2]•CH3CN 621.55 0.30 x 0.15 x 0.15 Orange Monoclinic P21/n

[Zn(C27H31N3)(NO3)2]•CH3CN 627.99 0.30 x 0.23 x 0.20 Yellow Monoclinic P21/c

9.5104 (1) 12.3747 (2) 26.2443 (4) 90.0 92.145 (1) 90.0 3086.48 (8) 4 1.338 0.61 1300 293 (2) 3.1-27.5 -12 ≤ h ≤ 12 -16 ≤ k ≤ 16 -34 ≤ l ≤ 34 30930 6993 5378 [I > 3(I)] 0.045 441 0.041 0.109 1.04 0.001 0.55 -0.30

14.6379 (2) 13.6490 (3) 16.2178 (3) 90.0 105.171 (2) 90.0 3094.82 (7) 4 1.348 0.84 1312 173 (2) 3.3-27.5 -18 ≤ h ≤ 18 -17 ≤ k ≤ 17 -21 ≤ l ≤ 20 46745 7047 5663 [I > 3(I)] 0.035 502 0.037 0.104 1.04 0.001 0.39 -0.33

R int   Fo2  Fo2

19

F

2 o

RI SC NU

MA

TE

AC CE P

Rint Parameters R Rw S Maximum /  Maximum (e/ Å3)  Minimum (e/ Å3)

D

Reflections measured Independent reflections Reflections

PT

Compound

, R1   Fo  Fc

F

o

, wR2 

 wF

2 o

 Fc2

  wF   2

2 2 o

1

2

ACCEPTED MANUSCRIPT

TE

AC CE P 20

SC

RI

4 2.313(2) 2.021(1) 2.260(2) 1.989(1) 2.749(2) 1.999(1) 2.695(2) 1.263(2) 1.273(3) 74.72(6) 151.08(6) 76.36(6) 100.44(6) 93.78(6) 135.64(6) 84.68(6) 138.49(6) 86.90(5) 99.98(6) 108.13(6) 51.10(6) 85.24(6) 171.42(6) 52.31(5)

MA

NU

1 2.250(1) 2.061(1) 2.280(1) 2.117(1) 2.312(1) 2.167(2) 2.191(1) 1.278(3) 1.277(2) 75.30(6) 149.90(6) 74.61(6) 117.14(6) 87.44(6) 139.85(6) 86.02(6) 142.47(6) 87.82(6) 86.50(6) 117.27(6) 57.28(5) 77.68(6) 173.56(6) 58.36(6)

D

Bond M-N1 M-N8 M-N10 M-O31 M-O33 M-O35 M-O37 C2-N1 C9-N10 N1-M-N8 N1-M-N10 N8-M-N10 N1-M-O31 N1-M-O35 N8-M-O31 N8-M-O33 N8-M-O35 N8-M-O37 N10-M-O31 N10-M-O35 O31-M-O33 O31-M-O35 O33-M-O37 O35-M-O37

PT

Table 2. Selected bond lengths (Å) and bond angles (°) for compounds 1 and 4.

ACCEPTED MANUSCRIPT Table 3. Cell-growth inhibitory assay results. IC50 value after 48 h of incubation. Compound HCT-15

169.0 (91.2-672.1)

68.6 (56.2-84.8)

407.1 (167.7-3576.7)

79.4 (66.0-98.9)

(1)

45.6 (37.2-38.5)

99.9 (64.2-201.4)

[Cu(L1)(NO3)2]

(3)

25.2 (15.2-33.7)

38.9 (26.2-59.2)

[Zn(L1)(NO3)2]

(4)

36.8 (27.2-45.1)